The Non Human Primate model of HIV infection has played an important role in selecting HIV vaccine candidates to be tested in human trials. The results of RV144 have lead to re-evaluate this model as a predictor of effectiveness for HIV vaccines.
RV144: Observations and Continuation
1) Results sorted based on the time of acquisition showed 50-60% efficacy during the 1st year of follow up; _limited durability of vaccine-induced immune responses?
2) Results sorted based on risk of infection showed 40% of protection in the low risk population and only 3.7% in the high-risk population.
NOTE: the study was not powered to assess durability or to inform on the efficacy according to risk of infection.
Get more details on this exciting trial by downloading the full presentation: role of the nonhuman primate model for HIV in defining correlates of protection observed in the RV144 Study: What next for HIV vaccines?
Â· Studies conducted in the non human primate model have contributed to the RV144
Â· Results of the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition
Â· The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination
Dr Monica Vaccari, Staff Scientist, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH
For more information about the topics discussed, please click here >